Many Americans May Get Hospice Care Too Late

Share this content:
Many Americans May Get Hospice Care Too Late
Many Americans May Get Hospice Care Too Late

(HealthDay News) -- Of the more than 1.5 million patients who received hospice care in the United States in 2013, one-third died within one week, according to a new report from the National Hospice and Palliative Care Organization.

"While many dying Americans are opting for hospice care at the end of their lives, far too many receive care for a week or less. We need to reach patients earlier in the course of their illness to ensure they receive the full benefits that hospice and palliative care can offer," J. Donald Schumacher, Psy.D., president and CEO of the National Hospice and Palliative Care Organization, said in a news release from the organization.

In the new report, the organization examined the growth, delivery, and quality of hospice care in the United States. The investigators found that 34.5 percent of hospice patients received care for seven days or less, while half of hospice patients received care for less than 18 days. Of all hospice care, 66 percent was provided where patients lived, including private homes, residential facilities, or nursing homes. The report authors noted that 91 percent of hospice care in 2013 was covered by the Medicare Hospice Benefit.

Meanwhile, the report revealed that most hospice patients had conditions other than cancer. "A common misconception is that hospices care predominantly for people with cancer," said Schumacher. The researchers found that 63 percent of the people who received hospice care were not cancer patients and had other illnesses, such as dementia, heart disease, lung disease, stroke, or kidney disease.

Full Article
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths